NCT06224660View on ClinicalTrials.gov

Modulation of SERCA2a of Intra-Myocytic Calcium Trafficking in Cardiomyopathy Secondary to Duchenne Muscular Dystrophy

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 2, 2024

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2030

Conditions
DMD-Associated Dilated Cardiomyopathy
Interventions
GENETIC

SRD-001

SRD-001 is an adeno-associated virus serotype 1 (AAV1) based gene therapy designed to deliver a copy of the gene encoding the human sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase 2a (SERCA2a). It is administered as a one-time intracoronary infusion.

Trial Locations (3)

43215

RECRUITING

Nationwide Children's Hospital, Columbus

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

66160

RECRUITING

The University of Kansas Medical Center, Kansas City

All Listed Sponsors
lead

Sardocor Corp.

INDUSTRY